OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
45607056

ENCell Co Ltd

Biotechnology & Medical ResearchVerified

ENCell Co Ltd exhibits a strong liquidity position, with a current ratio of 13.59, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to KRW 13,999,999,610, which is a substantial portion of its total assets of KRW 63,712,916,710. However, the company's operating cash flow is negative at KRW -10,197,459,800, and its free cash flow is also negative at KRW -14,550,495,720, suggesting that the company is not generating sufficient cash from operations to fund its activities. Profitability metrics for ENCell are weak, with a return on equity (ROE) of -0.4088 and a return on assets (ROA) of -0.2528. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income is negative at KRW -17,890,496,550, and its net income is also negative at KRW -16,107,525,270, reflecting ongoing losses. ENCell's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. The company's total revenue for the latest period is KRW 5,258,687,310, but there is no detailed breakdown of revenue by geographic region or product line in the provided data. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the input data. However, the negative operating and net income figures suggest that the company is not currently experiencing positive growth. The company's capital expenditures are negative at KRW -3,147,893,450, indicating a reduction in investment in long-term assets. Risk factors for ENCell include its negative cash flows and profitability, which could impact its ability to sustain operations without external financing. The company's debt-to-equity ratio is 0.33, which is relatively low, but the negative free cash flow and operating cash flow could increase financial risk if the company needs to raise additional capital. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. Recent events and filings do not indicate any significant changes in the company's financial position or strategic direction. The company's financial statements do not mention any recent acquisitions, partnerships, or regulatory changes that would impact its operations. The absence of detailed segment or geographic data limits the ability to assess the company's exposure to specific markets or products.

30-day price · 456070-2170.00 (-14.1%)
Low$12900.00High$16790.00Close$13220.00As of12 May, 00:00 UTC
Profile
CompanyENCell Co Ltd
Ticker456070.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. ENCell Co Ltd is a South Korean biotechnology company specializing in healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic products and services.

Classification. ENCell is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a high confidence level of 0.92 based on verified market data.

ENCell Co Ltd exhibits a strong liquidity position, with a current ratio of 13.59, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to KRW 13,999,999,610, which is a substantial portion of its total assets of KRW 63,712,916,710. However, the company's operating cash flow is negative at KRW -10,197,459,800, and its free cash flow is also negative at KRW -14,550,495,720, suggesting that the company is not generating sufficient cash from operations to fund its activities. Profitability metrics for ENCell are weak, with a return on equity (ROE) of -0.4088 and a return on assets (ROA) of -0.2528. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income is negative at KRW -17,890,496,550, and its net income is also negative at KRW -16,107,525,270, reflecting ongoing losses. ENCell's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. The company's total revenue for the latest period is KRW 5,258,687,310, but there is no detailed breakdown of revenue by geographic region or product line in the provided data. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the input data. However, the negative operating and net income figures suggest that the company is not currently experiencing positive growth. The company's capital expenditures are negative at KRW -3,147,893,450, indicating a reduction in investment in long-term assets. Risk factors for ENCell include its negative cash flows and profitability, which could impact its ability to sustain operations without external financing. The company's debt-to-equity ratio is 0.33, which is relatively low, but the negative free cash flow and operating cash flow could increase financial risk if the company needs to raise additional capital. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. Recent events and filings do not indicate any significant changes in the company's financial position or strategic direction. The company's financial statements do not mention any recent acquisitions, partnerships, or regulatory changes that would impact its operations. The absence of detailed segment or geographic data limits the ability to assess the company's exposure to specific markets or products.
Key takeaways
  • ENCell Co Ltd has a strong liquidity position with a current ratio of 13.59, but it is not generating positive cash flows from operations.
  • The company is experiencing significant losses, with a negative return on equity and return on assets.
  • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • The company's growth trajectory is uncertain, with no positive revenue growth projections provided.
  • Risk factors include negative cash flows and profitability, but the company's debt-to-equity ratio is low.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$5.26B
Gross profit-$2.40B
Operating income-$17.89B
Net income-$16.11B
R&D
SG&A
D&A
SBC
Operating cash flow-$10.20B
CapEx-$3.15B
Free cash flow-$14.55B
Total assets$63.71B
Total liabilities$24.31B
Total equity$39.40B
Cash & equivalents$14.00B
Long-term debt$13.02B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$39.40B
Net cash$984.3M
Current ratio13.6
Debt/Equity0.3
ROA-25.3%
ROE-40.9%
Cash conversion63.0%
CapEx/Revenue-59.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 254 companies
Metric456070Activity
Op margin-340.2%7.0% medp25 3.8% · p75 10.2%bottom quartile
Net margin-306.3%2.4% medp25 -0.6% · p75 5.4%bottom quartile
Gross margin-45.7%50.1% medp25 23.6% · p75 72.3%bottom quartile
CapEx / revenue-59.9%-6.8% medp25 -27.8% · p75 -1.7%bottom quartile
Debt / equity33.0%140.5% medp25 104.0% · p75 177.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:09 UTC#429e8845
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:11 UTCJob: 4f07cae9